UroGen Pharma Ltd.
NASDAQ:URGN
21.42 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 90.398 | 82.713 | 64.357 | 48.042 | 11.799 |
| Cost of Revenue
| 8.881 | 9.361 | 7.654 | 5.157 | 1.009 |
| Gross Profit
| 81.517 | 73.352 | 56.703 | 42.885 | 10.79 |
| Gross Profit Ratio
| 0.902 | 0.887 | 0.881 | 0.893 | 0.914 |
| Reseach & Development Expenses
| 57.145 | 45.614 | 52.906 | 47.642 | 47.31 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 121.154 | 93.274 | 82.838 | 87.535 | 90.219 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 178.299 | 138.888 | 135.744 | 135.177 | 137.529 |
| Operating Income
| -96.782 | -65.536 | -79.041 | -92.292 | -126.739 |
| Operating Income Ratio
| -1.071 | -0.792 | -1.228 | -1.921 | -10.742 |
| Total Other Income Expenses Net
| -27.26 | -32.788 | -28.987 | -17.079 | 1.629 |
| Income Before Tax
| -124.042 | -98.324 | -108.028 | -109.371 | -125.11 |
| Income Before Tax Ratio
| -1.372 | -1.189 | -1.679 | -2.277 | -10.603 |
| Income Tax Expense
| 2.832 | 3.92 | 1.755 | 1.449 | 3.374 |
| Net Income
| -126.874 | -102.244 | -109.783 | -110.82 | -128.484 |
| Net Income Ratio
| -1.404 | -1.236 | -1.706 | -2.307 | -10.889 |
| EPS
| -2.96 | -3.55 | -4.79 | -4.96 | -5.9 |
| EPS Diluted
| -2.96 | -3.55 | -4.79 | -4.96 | -5.9 |
| EBITDA
| -110.335 | -60.352 | -76.214 | -90.154 | -122.709 |
| EBITDA Ratio
| -1.221 | -0.73 | -1.184 | -1.877 | -10.4 |